{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:27:45Z","timestamp":1783711665255,"version":"3.55.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CSCR"],"published-print":{"date-parts":[[2012,12,2]]},"abstract":"\n\nDespite updating knowledge and a growing number of medications for multiple sclerosis (MS), no definite\ntreatment is available yet for patients suffering from progressive forms of the disease. Autologous bone marrow derived\nmesenchymal stem cell (BM-MSC) transplantation is a promising method proposed as a therapy for MS. Although the\nsafety of these cells has been confirmed in hematological, cardiac and inflammatory diseases, its efficacy in MS treatment\nis still under study.<\/jats:p><\/jats:sec>\n\n\n\nPatients with progressive MS (expanded disability status scale score: 4.0 \u20136.50) unresponsive to conventional treatments\nwere recruited for this study.<\/jats:p><\/jats:sec>\n\n\n\nTwenty-five patients [f\/m: 19\/6, mean age: 34.7\u00b17] received a single intrathecal injection of ex-vivo expanded MSCs\n(mean dose: 29.5&times;106 cells). We observed their therapeutic response for 12 months. Associated short-term adverse events\nof injection consisted of transient low-grade fever, nausea \/vomiting, weakness in the lower limbs and headache. No major\ndelayed adverse effect was reported. 3 patients left the study for personal reasons. The mean (SD) expanded disability\nstatus scale (EDSS) score of 22 patients changed from 6.1 (0.6) to 6.3 (0.4). Clinical course of the disease (measured by\nEDSS) improved in 4, deteriorated in 6 and had no change in 12 patients. In MRI evaluation, 15 patients showed no\nchange, whereas 6 patients showed new T2 or gadolinium enhanced lesions (1 lost to follow-up).<\/jats:p><\/jats:sec>\n\n\n\nIt seems that MSC therapy can improve\/stabilize the course of the disease in progressive MS in the first year after injection\nwith no serious adverse effects. Repeating the study with a larger sample size, booster injections and longer follow-up\nusing a controlled study design is advised.<\/jats:p><\/jats:sec>","DOI":"10.2174\/157488812804484648","type":"journal-article","created":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T02:37:00Z","timestamp":1355193420000},"page":"407-414","source":"Crossref","is-referenced-by-count":157,"title":["Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study"],"prefix":"10.2174","volume":"7","author":[{"given":"Mandana","family":"Mohyeddin Bonab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ali Sahraian","sequence":"additional","affiliation":[{"name":"Sina MS Research Center, Department of Neurology, Sina Hospital, Hassan Abad Square, Tehran, Iran., Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Aghsaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Ahmadi Karvigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed","family":"Massoud Hosseinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrouz","family":"Nikbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeideh","family":"Khorramnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Reza Motamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoureh","family":"Togha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hossien Harirchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Beladi Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Alikhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Yadegari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirous","family":"Jafarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Reza Gheini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Stem Cell Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/105324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/105324\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/105324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T19:40:40Z","timestamp":1618429240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/105324\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,2]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/157488812804484648","relation":{},"ISSN":["1574-888X"],"issn-type":[{"value":"1574-888X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12,2]]}}}